SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT01274208

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

Enhanced HCV Nonstructural Protein 3 (NS3) -Specific T Cell Proliferation,Interferon γ (IFNγ) and Interleukin-10 (IL-10) Secreting Clones, and Peripheral Blood Natural Killers T Cells ( NKT Cells) in Patients With Type I Gaucher Disease Infected With HCV : An Advantage in Anti Hepatitis Immunity?

Study objectives: - Investigate the anti-HCV response in patients with Gaucher disease(GD) - Define the potential role of high levels of Glucocerebroside in the immune system Study hypothesis: High levels of Glucocerebroside can be used as a tool in the antiviral treatment of hepatitis C by potentiating the immune response of natural killer T cells and dendritic cells

NCT01274208 Gaucher Disease Hepatitis C
MeSH:Hepatitis A Hepatitis C Hepatitis Gaucher Disease
HPO:Hepatitis


Primary Outcomes

Measure: Gaucher patients' immune system provide enhanced immunity against hepatitis c virus

Time: 6 months

Secondary Outcomes

Measure: the role Glucocerebroside level have by enhanced immunity in patients with Gaucher disease

Time: 30 days

Time Perspective: Prospective

Cohort


There is one SNP

SNPs


1 N370S

Of these mutations, N370S (or 1226G) occurs in 1 out of 17 Ashkenazi individuals, leading to a disease frequency of 1:850 in this ethnic group. --- N370S ---



HPO Nodes


HPO: